Wall Street analysts expect that LumiraDx Limited (NASDAQ:LMDX) will report earnings of ($0.08) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for LumiraDx’s earnings. The company is expected to report its next earnings report on Wednesday, February 9th.
According to Zacks, analysts expect that LumiraDx will report full-year earnings of $0.13 per share for the current year, with EPS estimates ranging from ($0.02) to $0.28. For the next financial year, analysts expect that the company will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.40) to ($0.39). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow LumiraDx.
LumiraDx (NASDAQ:LMDX) last announced its earnings results on Wednesday, November 10th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. The firm had revenue of $109.08 million during the quarter, compared to analyst estimates of $100.84 million.
Shares of NASDAQ LMDX opened at $9.41 on Friday. The company has a quick ratio of 1.65, a current ratio of 2.56 and a debt-to-equity ratio of 1.66. LumiraDx has a 52-week low of $7.15 and a 52-week high of $11.09. The firm has a 50-day moving average price of $9.19.
A number of institutional investors have recently bought and sold shares of LMDX. Citadel Advisors LLC acquired a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $317,000. Jane Street Group LLC acquired a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $224,000. Geode Capital Management LLC acquired a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $205,000. Morgan Stanley acquired a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $75,000. Finally, UBS Group AG acquired a new stake in shares of LumiraDx in the 3rd quarter valued at approximately $29,000.
LumiraDx Company Profile
LumiraDx Limited is a point of care diagnostics company. Its testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx Limited, formerly known as CA Healthcare Acquisition Corp., is based in BOSTON.
Featured Article: Balance Sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LumiraDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LumiraDx and related companies with MarketBeat.com's FREE daily email newsletter.